In February 10th, Porton Pharma Solutions Ltd(300363) announced its investment in the official WeChat official account, which will invest 260 million yuan to expand the CDMO production capacity of the raw material drug at the longevity production base in Chongqing.
The expansion project is 301 workshop of Changshou production base, with a planned reaction volume of 142.6m3, which is positioned as a medium-sized commercial GMP intermediate flexible production capacity. The project is expected to be put into operation in March 2023. After being put into operation, the total capacity of Changshou production base will be increased by 16% on the basis of the existing capacity of 900m3.
Workshop 301 is the second intelligent production workshop built by Porton Pharma Solutions Ltd(300363) after workshop 109 put into operation in June 2021. About 75% of the operating units of workshop 109 can be automated. On this basis, workshop 301 will realize the iterative upgrading of automation and intelligence. In addition, workshop 301 will continue to improve equipment adaptability to improve flexibility, meet the needs of different projects and realize efficient switching between projects.
Porton Pharma Solutions Ltd(300363) is a well-known pharmaceutical contract customization R & D and production enterprise in China. Its main business includes cdmo business of chemical raw materials, cdmo business of chemical agents and cdmo business of Biology (including gene therapy and cell therapy). With the development of the global pharmaceutical industry, cdmo is experiencing an era of rapid growth. Since then, CMO dominated by single capacity output has gradually transformed into cdmo dominated by technology output. In 2017, the global cdmo market was about $63 billion, and it is expected to reach $102.5 billion in 2021, with a compound annual growth rate of about 12.73%. In this context, Porton Pharma Solutions Ltd(300363) revenue growth has accelerated year by year. In the past three years, Porton Pharma Solutions Ltd(300363) revenue has increased from 1.5 billion to 3 billion.
